Why the study?
There is interest in developing simplified diagnostic algorithms for dysbetalipoproteinemia to avoid the complex testing associated with the Fredrickson criteria reference method.
What are the recent advances in the screening and diagnosis of dysbetalipoproteinemia?
What are the recent advances in the screening and diagnosis of dysbetalipoproteinemia?
Answers are grounded in this paper and cite their sources.
Measurement of apolipoprotein B and APOE gene testing are essential for diagnosing the heterogeneous phenotypes of dysbetalipoproteinemia.
PURPOSE OF REVIEW: In recent years, there has been interest for the development of simplified diagnosis algorithms of dysbetalipoproteinemia (DBL) in order to avoid the complex testing associated with the Fredrickson criteria (reference method). The purpose of this review is to present recent advances in the field of DBL with a focus on screening and diagnosis. RECENT FINDINGS: Recently, two different multi-step algorithms for the diagnosis of DBL have been published and their performance has been compared to the Fredrickson criteria. Furthermore, a recent large study demonstrated that only a minority (38%) of DBL patients are carriers of the E2/E2 genotype and that these individuals presented a more severe phenotype. SUMMARY: The current literature supports the fact that the DBL phenotype is more heterogeneous and complex than previously thought. Indeed, DBL patients can present with either mild or more severe phenotypes that can be distinguished as multifactorial remnant cholesterol disease and genetic apolipoprotein B deficiency. Measurement of apolipoprotein B as well as APOE gene testing are both essential elements in the diagnosis of DBL.
No takes yet. Share an insight, caveat, or question.
Paquette et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: